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sive surgical techniques have been available for over 20 years. By
the late 1990’s laparoscopy was seen internationally as the future
of general surgery. The ﬁrst laparoscopic cholecystecomy (LC) in
Trinidad had been performed in 1991. However, by 2003 this
procedure was still not being performed at public hospitals in
Trinidad and Tobago. Even in private hospitals only 7% of
cholecystectomies were being performed laparoscopically. This
was seen as a problem because LC is recognized as the ‘ﬁrst step’
towards more widespread use of laparoscopic procedures in
general surgery. A failure of the health system to adopt LC would
translate to a failure to develop general laparoscopic surgery.
Further, the population was being denied the well-documented
patient beneﬁts of LC in terms of reduced pain and shorter
recovery time.
Goals: The objective of the study was to gain an understanding of
the reasons for the failure to adopt laparoscopic cholecystectomy
more widely despite the presence of surgeons who were able to
perform the procedure and the availability of the required equip-
ment in private hospitals. Recommendations for action were to
be made based on these ﬁndings.
Outcomes items used in the decision: Surgeon and Administrator
opinions on the clinical and cost-effectiveness of LC compared to
Open Cholecystectomy (OC) and Minilap Cholecystectomy
(MC). A cost-effectiveness analysis was carried out comparing
these three procedures. Implementation Strategy: The views of
consultant surgeons about the clinical and economic impact of
LC versus other approaches, and their reasons for not perform-
ing were obtained by interview. Administrators in the Regional
Health Authorities were also interviewed to obtain information
about why LC had not been adopted in their hospitals. A meta-
analysis based cost-effectiveness analysis was conducted that
compared costs and beneﬁts measured at (a) the level of the
individual hospital and (b) the societal level for three procedures:
OC, MC and LC for public hospitals in Trinidad and Tobago.
Results: Investigations revealed widespread belief among sur-
geons and administrators that LC substantially increased cost to
the health care system. Over 60% of surgeons believed that MC
was the lowest cost approach. The cost-effectiveness analysis
showed that for Trinidad and Tobago, an LC programme would
result in substantial savings over OC and MC programmes both
at hospital level for society. Results of the cost-effectiveness
analysis along with the clinical potential of a laparoscopic
surgery programme (for example the potential for other mini-
mally invasive procedures that could be adopted) were presented
to physicians, administrators and policy makers in 2003–4. The
presentations were well received. Several hospitals were perform-
ing LC by 2005, and by 2007 all of the major hospitals had
acquired the necessary equipment and were performing LC. Post-
implementation data shows that LC is being performed well
within the limits of the key cost drivers in the CEA model, so that
cost savings are at least at predicted level.
Lessons Learned: Policy makers and clinicians responded to a
locally conducted cost-effectiveness analysis (albeit one using
published data from overseas). The diffusion-failure of LC
appeared largely to result from a failure to access relevant infor-
mation on cost-effectiveness and this represented a misallocation
of resources. The project pointed to the potential role for eco-
nomic evaluation methods in health resource allocation decision-
making in Trinidad and Tobago. A general framework for the
prioritization of health interventions is currently being developed
for Trinidad and Tobago. The aim is to develop a single frame-
work which can be used to inform resource allocation decisions
at various levels and which can be easily deployed in other
Caribbean islands. A review of criteria to guide explicit prioriti-
zation concluded with a recommendation that EuroQol EQ-5D
be used to obtain local values for health states which can in turn
be used to quantify the beneﬁts of health care interventions for
economic evaluations.
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Problem or Issue Addressed: Pharmacy budgets for cancer treat-
ment are ever increasing and are contributed to by the addition of
targeted therapies to standard cancer treatment regimens. As part
of our formulary management process, we conducted and pre-
sented an pre formulary admission and post admission economic
analysis of bortezomib in combination with standard chemo-
therapy for refractory or relapsed multiple myeloma.
Goals: The purpose of this project was to incorporate budget
impact and cost-effectiveness considerations into the Pharmacy
and Therapeutics Committee’s deliberations about the approval
for addition of a new product to the standard of care chemo-
therapy in the institution. A pre-approval economic model for
bortezomib was built, which included annual budget impact and
cost-effectiveness, and was presented to the Pharmacy and Thera-
peutics Committee in 2003. In 2007, a post-approval economic
analysis was presented again to the Pharmacy and Therapeutics
Committee in order to assess the actual annual budget impact of
bortezomib and compare it to the pre-approval economic model.
Outcomes items used in the decision: The institutional annual
budget impact analysis was done using direct medical costs,
in 2007 United States Dollars. A cost per life year saved was
also calculated for the initial Pharmacy and Therapeutics
consideration.
Implementation Strategy: A model was built based on the
indication of treatment of relapsed and refractory multiple
myeloma as third line treatment. Assumptions regarding bort-
ezomib’s number of doses per cycle, per patient and median
number of cycles per patient were based on information from
published clinical trials. Annual budget impact for the expected
MD Anderson population of 25 multiple myeloma patients,
adjusted for 2007, was calculated to be $414,974 and a cost
per life year saved was calculated as $14,592. This model,
along with a clinical monograph, was presented to the P&T
Committee at the same time as the vote for bortezomib’s inclu-
sion onto formulary. Subsequently, bortezomib was added to
the formulary as an add-on drug for refractory or relapsed mul-
tiple myeloma patients with two prior therapies, and with the
recommendation that physicians use discretion for use outside
the FDA-indication.
Results: We reviewed non-investigational usage of bortezomib in
MDACC from June 2006 to May 2007, after allowing ample
time since its addition to the formulary to penetrate the institu-
tion. We had a total of 161 patients on bortezomib. Of these, 140
(87%) were refractory or relapsed multiple myeloma patients
who had prior therapies, 7 (4%) were mantle cell lymphoma
patients with prior treatments, and 14 (9%) patients received
bortezomib for non FDA-approved indications. Refractory or
relapsed multiple myeloma was FDA-approved in March, 2005
for second line therapy, whereas mantle cell lymphoma was
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FDA-approved in December 2006, during our study period. We
also reviewed charges and reimbursement data collected for the
drug from June 2006 to December 2006. For the duration of the
study period, we had a positive margin and our reimbursement to
charge rate for multiple myeloma patients was close to MDACC
goal of 55%, with 53.3% rate overall. Based on this analysis,
there were some differences between the model assumptions and
our ﬁndings from actual data. Our model had predicted 100%
usage for the FDA approved indication of multiple myeloma in
the expected patient population of 25 patients. Actual data col-
lected showed that not only did we have more than expected
number of patients on bortezomib, potentially due to the change
in labeling to an earlier stage of disease, but our model had
assumed 4 cycles of bortezomib therapy per patient whereas the
actual average number of cycles per patient was only 2 at our
institution. We did not have data to determine whether the
patients had obtained more cycles of therapy from other
providers.
Lessons Learned: Annual budget impact analysis helped estimate
the cost to the institution for adding bortezomib to the formu-
lary. Performing an annual budget impact before the addition of
a drug to an institution’s formulary, and comparing it with the
annual budget impact after a few years of the drug being on the
formulary, is an essential process in determining the best use of
scarcely available, expensive resources for the most appropriate
use. Cost effectiveness studies, that take costs of treatments and
their outcomes in patients into account, are as important in
allocating resources to best possible use in this era of rising costs
and future research will focus on calculating cost-effectiveness
speciﬁcally for the institution’s patient population.
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Problem or Issue Addressed: With the fast pace of new medical
technologies launched into the market, it is imperative to develop
a formal and methodical approach to assess and evaluate out-
comes and impacts; one that goes beyond the short-term vision of
price and volume negotiation. Although there are several agen-
cies across the globe that evaluate technologies, not always the
market can count on their results because 1) either these reports
are based on scenarios that don’t reﬂect the real situation (for
instance, a health plan in Africa considering a report about the
U.S. medical system), or 2) there is not enough time to wait for
a conclusion.
Goals: Effective coverage and Reimbursement decisions must
reﬂect the local scenarios where they happen, and new methods
to evaluate medical technologies must be in place to allow distant
markets to reach their own conclusions about health care. One
proposed answer to this problem is to bring different market
stakeholders to teamwork and develop an approach that com-
bines everyone’s expertise into an effective methodology reﬂect-
ing the local market scenario and population. In summary, to
develop a Health Technology Assessment that reﬂects the local
health care scenario and that is agile enough for a Health Plan.
Outcomes items used in the decision: Cost-effectiveness data
(literature and local), local prevalence and incidence disease
rates.
Implementation Strategy: Presentation and validation of meth-
odology to Cassi and J&J Executive Board. Communication of
new HTA process to all Cassi’s franchises and J&J divisions in
Brazil.
Results: Work in Progress. One technology assessed, another in
evaluation. Cassi hopes to decrease medical costs and improve
health care outcomes in 2008. J&J hopes to improve negotia-
tions with Cassi.
Lessons Learned: Developing nations cannot count solely on
studies performed in developed countries; they must develop
analyses that reﬂect local scenarios and markets. To improve
value for patients, one stakeholder cannot act alone. All partici-
pants must take action to improve the health care system’s
efﬁciency.
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Problem or Issue Addressed: Development of methods for eco-
nomic assessment of (mostly) new drugs and other interventions.
Goals: Provide clear, useful information to the German Federal
Joint Committee for use in the setting of ceiling prices. Meet the
special requirements of the German context, while remaining
consistent with international standards of health economic
assessment.
Outcomes items used in the decision: Plotting of the efﬁciency
frontier within a speciﬁc therapeutic area to display the position
of existing therapies and provide guidance for decisions through
demarcation of various zones for new therapies. Horizontal axis
consisting of the expected total cost per patient in Germany.
Vertical axis consisting of a cardinal scal of value tha reﬂects the
beneﬁt assessed beforehand by IQWiG.
Implementation Strategy: International Expert Panel convened to
develop the Methods. Draft Recommendations presented to
broadening circle of German experts and constituencies culmi-
nating in Public consultation in January 2008.
Results: The core Recommendations will be presented along with
their rationale, interpretation and use in guiding decision makers.
A worked out example will be used to illustrate the implications.
Lessons Learned: It is possible to develop Methods that provide
for economic evaluation within the constraints posed in
Germany. This is done by focusing on the narrower objective of
efﬁciency within a therapeutic area rather than the much loftier
goal of relative valuation across the health care system.
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Problem or Issue Addressed: There currently exists a lack of
sufﬁcient long-term cost-effectiveness data on new technologies
and new devices, in order to allow health care decision makers to
make good decisions. At the same time, the costs associated with
many of these technologies and devices have out-paced the level
of reimbursement given to the providers.
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